Welcome to our dedicated page for Pediatrix Medical Group SEC filings (Ticker: MD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pediatrix Medical Group, Inc. (NYSE: MD) files reports and disclosures with the U.S. Securities and Exchange Commission that provide detailed information about its physician services business focused on women, babies and children. As a Florida corporation with securities registered under Commission File Number 001-12111, Pediatrix uses SEC filings to report operating results, governance changes and significant corporate actions.
On this page, investors can review current and historical filings such as Form 8-K reports that Pediatrix uses to announce quarterly and annual financial results, including net revenue, net income, Adjusted EBITDA and Adjusted EPS. These filings often incorporate earnings press releases by reference and explain how factors like same-unit revenue growth, patient volumes, reimbursement-related trends, payor mix and practice dispositions affect performance. Other 8-K filings describe material events such as the authorization of a share repurchase program or the appointment of new directors to the board.
In addition to event-driven 8-K filings, Pediatrix’s broader SEC reporting (including annual and quarterly reports when available) provides context on its physician services model, focus on neonatology, obstetrics, maternal-fetal medicine and pediatric subspecialties, and the impact of transformational and restructuring related expenses, impairment items and capital structure on its results. These documents also reference non-GAAP measures and include reconciliations to the most directly comparable GAAP measures.
Stock Titan’s SEC filings page for MD is designed to surface these disclosures in one place and to pair them with AI-powered summaries that explain key points in clear language. Users can quickly see what each filing covers, how it relates to Pediatrix’s hospital-based and pediatric subspecialty services, and where items such as share repurchase authorizations, director appointments and portfolio management updates are discussed. This helps investors and researchers interpret complex filings and track how regulatory disclosures reflect the company’s evolving operations.